Active Filter(s):
Details:
si-544, the Company´s drug candidate, is blocking Kv1.3, a specific ion channel involved in the activation and proliferation of TEM cells. It is being developed in Phase 1 trial in atopic dermatitis patients.
Lead Product(s): si-544
Therapeutic Area: Dermatology Product Name: si-544
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023